全身磁共振成像与[18F]FDG PET/CT在浆细胞瘤诊断与监测中的比较研究
该多中心回顾性观察研究纳入2012至2023年间73例浆细胞瘤患者,其中56例同时接受全身磁共振成像(WB-MRI)和[18F]FDG PET/CT检查。WB-MRI检出98.2%的浆细胞瘤,[18F]FDG PET/CT检出83.9%,差异有统计学意义(OR 9,95%CI 1.2-394.5,P=0.021)。作者认为WB-MRI可作为[18F]FDG PET/CT检测浆细胞瘤的替代方法,全面的临床和影像学评估对浆细胞瘤患者的最佳评价至关重要。
要点
- WB-MRI检出98.2%的浆细胞瘤,[18F]FDG PET/CT检出83.9%,差异有统计学意义(OR 9,95%CI 1.2-394.5,P=0.021)。
- 骨浆细胞瘤两种检查一致性很高,髓外浆细胞瘤一致性中等。
- 作者认为WB-MRI可作为[18F]FDG PET/CT检测浆细胞瘤的替代方法。
核心结论
- 作者认为WB-MRI可作为[18F]FDG PET/CT检测浆细胞瘤的替代方法。
- 全面的临床和影像学评估对浆细胞瘤患者的最佳评价至关重要。
研究设计与样本
- 多中心、观察性、回顾性分析,纳入2012至2023年间诊断为浆细胞瘤并接受WB-MRI和/或[18F]FDG PET/CT作为诊断检查一部分的患者。
- 共纳入73例患者(33例男性),年龄范围30-94岁(平均63.4±12.2岁),其中56例同时接受两种检查。
- 诊断包括孤立性浆细胞瘤16例、同时合并多发性骨髓瘤(MM)和浆细胞瘤18例、有MM病史的浆细胞瘤22例。
- 56个浆细胞瘤中,40个为骨性,16个为髓外。
- 采用McNemar检验和Pearson χ2检验比较WB-MRI与[18F]FDG PET/CT的检出率。
主要发现
- WB-MRI检出98.2%的浆细胞瘤,[18F]FDG PET/CT检出83.9%,差异有统计学意义(OR 9,95%CI 1.2-394.5,P=0.021)。
- 骨浆细胞瘤两种检查一致性很高,髓外浆细胞瘤一致性中等。
关键数值与推荐
- 当前指南推荐[18F]FDG PET/CT作为疑似髓外骨浆细胞瘤的首选影像学方法,而WB-MRI适用于孤立性骨浆细胞瘤。
临床怎么用
- 作者认为WB-MRI可作为[18F]FDG PET/CT检测浆细胞瘤的替代方法。
- 作者认为全面的临床和影像学评估对浆细胞瘤患者的最佳评价至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Current guidelines recommend [ 18 F]FDG PET/CT as the preferred imaging modality for suspected extramedullary bone plasmacytomas, while whole-body magnetic resonance imaging (WB-MRI) is indicated for solitary bone plasmacytomas. Despite these recommendations, the available evidence comparing the diagnostic efficacy of both techniques remains limited. The aim of this study was to compare the diagnostic efficacy of WB-MRI and [ 18 F]FDG PET/CT in the initial evaluation of plasmacytomas. METHODS: We performed a multicenter, observational, and retrospective analysis of patients diagnosed with plasmacytoma who underwent WB-MRI and/or [ 18 F]FDG PET/CT as part of their diagnostic workup. Lesions identified were categorized by anatomic location, and concordance between WB-MRI and [ 18 F]FDG PET/CT findings was assessed. The McNemar test and Pearson χ 2 test were used to compare detection rates between WB-MRI and [ 18 F]FDG PET/CT. RESULTS: The study included 73 patients (33 men) recruited between 2012 and 2023, age range 30-94 years (mean 63.4 ± 12.2 y). Of these, 56 patients underwent both diagnostic tests. Diagnoses revealed solitary plasmacytoma in 16 patients, concurrent multiple myeloma (MM) and plasmacytoma in 18 patients, and plasmacytoma in 22 patients with a prior MM history. Out of the 56 plasmacytomas, 40 were osseous and 16 were extramedullary. WB-MRI detected 98.2% of plasmacytomas compared with 83.9% for [ 18 F]FDG PET/CT, with a statistically significant difference of OR 9 (95% CI: 1.2-394.5), P =0.021. Concordance was very high for osseous plasmacytomas but moderate for extramedullary plasmacytomas. CONCLUSIONS: These findings suggest WB-MRI is an alternative to [ 18 F]FDG PET/CT for detecting plasmacytomas. A comprehensive clinical and radiologic assessment is essential for the optimal evaluation of patients with plasmacytoma.
引用
- Gómez León N, Vicuña-Andrés I, Aguado-Bueno B, et al. Whole-body MRI Versus [ 18 F]FDG PET/CT in Diagnosing and Monitoring Plasmacytomas : A Comparative Study. Clin Nucl Med. 2025. PMID: 40375446. doi:10.1097/RLU.0000000000005954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。